RELMADA THERAPEUTICS INC (RLMD)
US75955J4022 - Common Stock
ChartMill assigns a Buy % Consensus number of 78% to RLMD. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 11.09. This target is 201.43% above the current price.
RLMD was analyzed by 11 analysts. The buy percentage consensus is at 78. So analysts seem to be have mildly positive about RLMD.
In the previous month the buy percentage consensus was at a similar level.
RLMD was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-06-15 | Mizuho | Reiterate | Buy -> Buy |
| 2023-01-23 | SVB Leerink | Maintains | Outperform |
| 2022-10-14 | Guggenheim | Downgrade | Buy -> Neutral |
| 2022-10-14 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2022-10-13 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-09-23 | Goldman Sachs | Maintains | Buy |
| 2022-09-06 | Guggenheim | Maintains | Buy |
| 2022-05-09 | Oppenheimer | Maintains | Outperform |
| 2021-12-20 | SVB Leerink | Maintains | Outperform |
| 2021-11-18 | Mizuho | Initiate | Buy |